Roivant Sciences Ltd (NASDAQ: ROIV) on Monday, plunged -0.50% from the previous trading day, before settling in for the closing price of $11.90. Within the past 52 weeks, ROIV’s price has moved between $8.24 and $13.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 493.24% over the last five years. The company achieved an average annual earnings per share of -114.22%. With a float of $376.18 million, this company’s outstanding shares have now reached $806.68 million.
The firm has a total of 908 workers. Let’s measure their productivity. In terms of profitability, gross margin is 88.72%, operating margin of 3057.91%, and the pretax margin is 2937.2%.
Roivant Sciences Ltd (ROIV) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Roivant Sciences Ltd is 49.13%, while institutional ownership is 61.95%. The most recent insider transaction that took place on Sep 26 ’24, was worth 10,354,320. In this transaction Director by Deputization of this company sold 876,000 shares at a rate of $11.82, taking the stock ownership to the 22,179,358 shares. Before that another transaction happened on Sep 25 ’24, when Company’s Director by Deputization sold 50,000 for $11.77, making the entire transaction worth $588,500. This insider now owns 23,055,358 shares in total.
Roivant Sciences Ltd (ROIV) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.4 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.31) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -114.22% per share during the next fiscal year.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Roivant Sciences Ltd (ROIV) is currently performing well based on its current performance indicators. A quick ratio of 27.75 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.57, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Analysing the last 5-days average volume posted by the [Roivant Sciences Ltd, ROIV], we can find that recorded value of 4.18 million was lower than the volume posted last year of 6.06 million. As of the previous 9 days, the stock’s Stochastic %D was 88.38%. Additionally, its Average True Range was 0.30.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 60.23%, which indicates a significant decrease from 80.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.70% in the past 14 days, which was lower than the 27.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.63, while its 200-day Moving Average is $11.07. Now, the first resistance to watch is $11.91. This is followed by the second major resistance level at $11.98. The third major resistance level sits at $12.08. If the price goes on to break the first support level at $11.74, it is likely to go to the next support level at $11.64. Now, if the price goes above the second support level, the third support stands at $11.57.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
Market capitalization of the company is 8.76 billion based on 738,722K outstanding shares. Right now, sales total 124,800 K and income totals 4,349 M. The company made 55,130 K in profit during its latest quarter, and 95,300 K in sales during its previous quarter.
